Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
92.85
(
1.63%
)
Bitcoin
73,329.96
(
-0.31%
)
News Focus
News Focus
Post# of 257665
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 245403

Wednesday, 02/08/2023 9:46:22 AM

Wednesday, February 08, 2023 9:46:22 AM

Post# of 257665
BMY/JNJ do not consider Abelacimab direct competition for Milvexian. Abelacimab is not oral, and its phase-3 program is targeting a niche market (Cancer Associated Thrombosis).

Bayer presumably has the same viewpoint as BMY/JNJ. although I haven't heard Bayer comment on this first-hand.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up